MedImmune's respiratory therapy granted FDA fast track designation
MedImmune, the biologics arm of Anglo-Swedish drug major AstraZeneca (LSE: AZN) has announced that it has been granted fast track designation by the US Food and Drug Administration for MEDI8897.
The high-potency, extended-half life monoclonal antibody is being investigated for the prevention of lower respiratory tract illness caused by respiratory syncytial virus in pediatric patients. The fast track designation is designed to accelerate the development and review of drugs treating serious conditions and fill an unmet medical need.
MedImmune has previously discovered, developed and currently markets a monoclonal antibody for severe respiratory syncytial virus disease and aims to increase the number of infants protected from lower respiratory tract infectious caused by the virus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze